Share

August 2021; 11 (4) ReviewOpen Access

Multiple Sclerosis Phenotypes as a Continuum

The Role of Neurologic Reserve

Timothy L. Vollmer, Kavita V. Nair, Ian M. Williams, Enrique Alvarez
First published January 29, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001045
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2085

Share

Article Information

vol. 11 no. 4 342-351
DOI: 
https://doi.org/10.1212/CPJ.0000000000001045
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received May 6, 2020
  • Accepted December 10, 2020
  • First Published January 29, 2021.

Article Versions

Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Timothy L. Vollmer, MD,
    2. Kavita V. Nair, MD,
    3. Ian M. Williams, PhD and
    4. Enrique Alvarez, MD
  1. Timothy L. Vollmer, MD,
    2. Scientific Advisory Boards:

    1. (1) Genentech/Roche

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) Combination therapy of rituximab and glatiramer acetate

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) University of Colorado School of Medicine

    Consultancies:

    1. (1) Biogen, (2) Genentech/Roche, (3) Siranax, (4) Celgene, (5) EMD Serono, (6) Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Celgene, (2) Biogen, (3)Anokion, (4) Genentech, (5) F. Hoffmann-La Roche Ltd, (6) GW Pharma, (7) TG Therapeutics, Inc.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Rocky Mountain MS Center

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Kavita V. Nair, MD,
    3. Scientific Advisory Boards:

    1. Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Commercial or non profit entity American Academy of Neurology

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Bristol Meyers Squibb Novartis Genentech

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Novartis, Genentech

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ian M. Williams, PhD and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Oxford PharmaGenesis Ltd, Communications Consultant, 4+ years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Enrique Alvarez, MD
    5. Scientific Advisory Boards:

    1. Actelion/Janssen, Alexion, Bayer, Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Genzyme, Novartis, Sanofi, and TG Therapeutics

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, Genentech/Roche, Novartis, TG Therapeutics,

    Research Support, Government Entities:

    1. Patient-Centered Outcomes Research Initiative, National Institutes of Health

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society, and Rocky Mountain MS Center

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology (TLV, KVN, EA), University of Colorado, and Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora; Department of Clinical Pharmacy (KVN), Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora; and Oxford PharmaGenesis (IMW), United Kingdom.
  1. Correspondence
    Prof. Vollmer Timothy.Vollmer{at}ucdenver.edu
View Full Text

Article usage

Article usage: January 2021 to April 2023

AbstractFullPdfSource
Jan 202139014Highwire
Feb 20212500126Highwire
Mar 2021252088Highwire
Apr 202169025Highwire
May 202166039Highwire
Jun 202166054Highwire
Jul 202166047Highwire
Aug 2021276364202Highwire
Sep 20211671031268Highwire
Oct 20211966586Highwire
Nov 20211017382Highwire
Dec 2021334381Highwire
Jan 2022925460Highwire
Feb 2022826252Highwire
Mar 20221416280Highwire
Apr 20221012955Highwire
May 20225358163Highwire
Jun 20221314148Highwire
Jul 2022815551Highwire
Aug 20222413149Highwire
Sep 20223714963Highwire
Oct 20221112054Highwire
Nov 20221615561Highwire
Dec 20221810337Highwire
Jan 20231014152Highwire
Feb 20231317845Highwire
Mar 20231513944Highwire
Apr 2023158559Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles